The current standard for diagnosis of Eosinophilic Esophagitis (EoE) is endoscopy with esophageal biopsy to determine the eosinophil count. A non-invasive biomarker of eosinophil activation would be helpful in management. A recent study investigated urinary 3-bromotyrosine (3-BT) measurements as a possible biomarker.
An assay called the Eosinophil Quantitated Urine Kinetic was developed. In the EoE patients, median urinary 3-BT level was 93 times higher than the nonatopic (nonallergic) group and 13 times higher than the atopic (allergic) group. Subjects with urine 3-BT level greater than 20pg/400mg of creatinine were 4.8 times more likely to have EoE compared to atopic controls. An atopic disease flare was not associated with any difference in urinary 3-BT.
Urinary 3-BT is an exciting assay that may assist allergists for the diagnosis of EoE.
You Might Also Enjoy...
Two large trials, DREAM and MENSA have found IL-5 therapy with mepolizumab to lower risk of exacerbation in patients with asthma with an eosinophilic phenotype.
Mold allergy is difficult to diagnose due to lack of standardized test material.
Skin prick testing and serum IgE measurement are limited in their ability to predict positive or negative responses to oral peanut challenge.
Bronchial Thermoplasty (BT) has been shown to result in significant improvements in a number of asthma control measures in three randomized clinical trials in patients with moderate-to-severe, persistent asthma.
Recent studies have suggested that early regular exposure to allergenic foods may reduce the risk of food allergy.
